PGT Awarded NHS Grant to Fund Pharmacogenetic Study on Patient Response to Breast Cancer Chemotherapy
March 10, 2010
Population Genetics technologies (PGT) Ltd, a privately owned company based in Cambridge, UK today announced that it has been awarded a grant from the National Institute for Health Research (NIHR) as part of the Institute’s Invention for Innovation (i4i) Programme.
The i4i Programme provides investment in, and improved identification of, promising healthcare technologies in order to accelerate the development of new healthcare products for the 21st century. The i4i programme funds translational research, extending between basic research and pre-clinical trials, or health technology assessments. Read more
PGT Appoints New VP of Business Development
May 25, 2009
Population Genetics Technologies (PGT) Ltd today announced the appointment of Dr Frank Massam as Vice President of Business Development. The move follows the recent announcement of a £2,000,000 second tranche of Series A funding to further develop and commercialize PGT’s suite of proprietary technologies. Read more
PGT Secures Final £2,000,000 of Series A Funding
May 20, 2009
Population Genetics technologies (PGT) Ltd, a privately owned company based in Cambridge, UK today announced that it had successfully met the commercial and development milestones set by its principal investors thereby securing its final £2,000,000 of Series A funding. Read more
PGT Raises £3.8 Million in Series A Funding; Appoints Mel N. Kronick Chief Executive Officer
February 19, 2008
Cambridge, UK – 19 February 2008 – Population Genetics Technologies Limited (‘PGT’), a privately-held company focused on creating new paradigms for performing large-scale population genetics studies, today announced that it has raised £3.8 million in a first round of venture funding. The venture financing was provided by Auriga Partners, Noble Fund Managers, and Compass Genetics Investors LLC (the founders of PGT: Drs. Sydney Brenner, Sam Eletr and Philip Goelet).